{"id":"https://openalex.org/W4256526460","doi":"https://doi.org/10.1182/blood-2018-99-118990","title":"A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions","display_name":"A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions","publication_year":2018,"publication_date":"2018-11-29","ids":{"openalex":"https://openalex.org/W4256526460","doi":"https://doi.org/10.1182/blood-2018-99-118990"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2018-99-118990","doi":"https://doi.org/10.1182/blood-2018-99-118990","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-118990","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058597775","display_name":"Juliana V\u00e9lez Luj\u00e1n","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Juliana Velez Lujan","raw_affiliation_strings":["Moores Cancer Center, University of California, San Diego, La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moores Cancer Center, University of California, San Diego, La Jolla, CA","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075436982","display_name":"Michael Y. Choi","orcid":"https://orcid.org/0000-0002-9107-2186","observed_orcids":["https://orcid.org/0000-0002-9107-2186"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Y. Choi","raw_affiliation_strings":["Moores Cancer Center, University of California, San Diego, La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moores Cancer Center, University of California, San Diego, La Jolla, CA","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076498481","display_name":"Chaja Feige Jacobs","orcid":"https://orcid.org/0000-0002-7294-4364","observed_orcids":["https://orcid.org/0000-0002-7294-4364"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Chaja Jacobs","raw_affiliation_strings":["Moores Cancer Center, University of California, San Diego, La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moores Cancer Center, University of California, San Diego, La Jolla, CA","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101093654","display_name":"Colin McCarthy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Colin McCarthy","raw_affiliation_strings":["Moores Cancer Center, University of California, San Diego, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moores Cancer Center, University of California, San Diego, San Diego, CA","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062305797","display_name":"Alaina Heinen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alaina Heinen","raw_affiliation_strings":["Moores Cancer Center, University of California, San Diego, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moores Cancer Center, University of California, San Diego, San Diego, CA","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062789679","display_name":"Carlos I. Amaya-Chanaga","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210133061","display_name":"Pharmacyclics (United States)","ror":"https://ror.org/03hm8w204","country_code":"US","type":"company","lineage":["https://openalex.org/I4210133061"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Carlos Amaya-Chanaga","raw_affiliation_strings":["Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA","institution_ids":["https://openalex.org/I4210133061"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036828560","display_name":"Thomas J. Kipps","orcid":"https://orcid.org/0000-0002-0064-4549","observed_orcids":["https://orcid.org/0000-0002-0064-4549"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas J. Kipps","raw_affiliation_strings":["Moores Cancer Center, University of California School, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moores Cancer Center, University of California School, San Diego, CA","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5013814515","display_name":"Januario E. Castro","orcid":"https://orcid.org/0000-0003-2785-0892","observed_orcids":["https://orcid.org/0000-0003-2785-0892"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4210127938","display_name":"Mayo Clinic Hospital","ror":"https://ror.org/03660jn93","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099","https://openalex.org/I4210127938"]},{"id":"https://openalex.org/I4390039332","display_name":"Mayo Clinic Comprehensive Cancer Center (Arizona)","ror":"https://ror.org/003xpy695","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099","https://openalex.org/I4390039332"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Januario E Castro","raw_affiliation_strings":["Cancer Center, Mayo Clinic, Phoenix, AZ","Cancer Center, UCSD, Phoenix, AZ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Center, Mayo Clinic, Phoenix, AZ","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4210127938","https://openalex.org/I4390039332"]},{"raw_affiliation_string":"Cancer Center, UCSD, Phoenix, AZ","institution_ids":["https://openalex.org/I36258959"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5062789679","https://openalex.org/A5076498481"],"corresponding_institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4210133061","https://openalex.org/I4390039236"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"132","issue":"Supplement 1","first_page":"1863","last_page":"1863"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9259999990463257},{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":0.9919999837875366},{"id":"https://openalex.org/keywords/obinutuzumab","display_name":"obinutuzumab","score":0.9869999885559082},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.7639999985694885},{"id":"https://openalex.org/keywords/anti-cd20-monoclonal-antibody","display_name":"anti-CD20 monoclonal antibody","score":0.9800000190734863},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7990000247955322},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.7739999890327454},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.7829999923706055},{"id":"https://openalex.org/keywords/comorbidity","display_name":"comorbidities","score":0.6970000267028809},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5370000004768372},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.6620000004768372},{"id":"https://openalex.org/keywords/lymphocytosis","display_name":"lymphocytosis","score":0.6890000104904175},{"id":"https://openalex.org/keywords/chromosomal-abnormalities","display_name":"chromosomal abnormalities","score":0.5849999785423279}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8449045419692993},{"id":"https://openalex.org/C2777607594","wikidata":"https://www.wikidata.org/wiki/Q389496","display_name":"Obinutuzumab","level":4,"score":0.8210903406143188},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.8019430637359619},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.607555627822876},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5898176431655884},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.5535510182380676},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4611077904701233},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.43963950872421265},{"id":"https://openalex.org/C2779015954","wikidata":"https://www.wikidata.org/wiki/Q420164","display_name":"Alemtuzumab","level":3,"score":0.4376411437988281},{"id":"https://openalex.org/C2780126324","wikidata":"https://www.wikidata.org/wiki/Q612345","display_name":"Lymphocytosis","level":2,"score":0.43614402413368225},{"id":"https://openalex.org/C2779788671","wikidata":"https://www.wikidata.org/wiki/Q998803","display_name":"Tumor lysis syndrome","level":3,"score":0.4248274266719818},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.35436350107192993},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3506973385810852},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3385043144226074},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.06711483001708984}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2018-99-118990","doi":"https://doi.org/10.1182/blood-2018-99-118990","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-118990","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2900694112","https://openalex.org/W2970930925","https://openalex.org/W2915066039","https://openalex.org/W2940552296","https://openalex.org/W97712808","https://openalex.org/W2393925508","https://openalex.org/W2921642800","https://openalex.org/W4200084991","https://openalex.org/W4283326254","https://openalex.org/W2988038735"],"abstract_inverted_index":{"Abstract":[0],"Standard":[1],"treatment":[2,381,394,400,484,496],"for":[3,133,162,179,192,320,455],"patients":[4,43,63,88,150,185,214,223,273,278,300,352,384,428,452,470,488,521,564,577,589],"with":[5,27,96,131,140,151,279,360,369,395,527,553],"chronic":[6],"lymphocytic":[7],"leukemia":[8],"(CLL)":[9],"is":[10,38,68],"rapidly":[11],"evolving":[12],"and":[13,24,76,110,114,167,177,234,264,308,339,365,407,422,440,445,485,516,560,586,609,621,665,697],"gradually":[14],"has":[15,544,598],"incorporated":[16],"the":[17,107,112,205,213,222,253,277,318,366,398,469,480,533,554,619],"combined":[18],"use":[19],"of":[20,74,79,94,127,136,146,202,212,221,271,348,376,405,464,468,483,495,510,518,558,575,583,588,604,623,659,667,691,699,717,730,752,775,789,800],"monoclonal":[21],"antibodies":[22],"(mAbs)":[23],"targeted":[25],"therapy":[26,135],"small":[28],"molecules.":[29],"Single":[30],"agent":[31,66],"Ibrutinib":[32],"(Ibr),":[33],"a":[34,101,225,230,472,513,524,600],"first-in-class":[35],"BTK":[36],"inhibitor,":[37],"effective":[39],"in":[40,62,129,258,262,266,475,532,569],"previously":[41,148],"untreated":[42,138,149],"including":[44],"those":[45],"that":[46,371,565,614],"are":[47],"older":[48],"than":[49,492],"65":[50,216],"or":[51,379,719,732,754,777,791,802],"considered":[52],"unfit":[53],"to":[54,181,433,497],"receive":[55],"chemotherapy-based":[56],"combinations.":[57],"The":[58,92,142,209,241,412,502,508,563],"complete":[59,77,115,525],"response":[60,72,78,116,193,456,504,515,579],"rate":[61,73,505,603],"receiving":[64],"single":[65],"Ibr":[67,95,128,168,431,559,567,615],"relatively":[69],"low":[70,602],"(overall":[71],"86%":[75],"4%":[80],"based":[81,157],"on":[82,158,713,726,748,771,785,796],"2008":[83,195,459],"iwCLL":[84,196,460],"criteria),":[85],"though":[86],"most":[87,413],"have":[89,550],"durable":[90],"remissions.":[91],"combination":[93,130,543,584],"mAbs":[97],"like":[98],"Obinutuzumab-Gazyva":[99],"(G),":[100],"third-generation":[102],"anti-CD20":[103],"mAb,":[104],"can":[105,616],"ameliorate":[106],"Ibr-induced":[108],"lymphocytosis":[109],"increase":[111],"overall":[113,503],"rates.":[117],"Accordingly,":[118],"we":[119],"initiated":[120],"an":[121,237,499,657,675,679,689,707,714,727,749,772,786,797,814],"open-label":[122],"phase":[123],"Ib/II":[124],"clinical":[125],"study":[126,143,380,399,661,693],"G":[132,155,175,321,561,624],"first-line":[134],"previous":[137],"pts":[139,511],"CLL.":[141,152],"completed":[144],"enrollment":[145],"32":[147],"Patients":[153,189,251],"received":[154,186],"administered":[156],"FDA":[159],"dosing":[160],"recommendations":[161],"6":[163,581],"cycles":[164,494],"(28":[165],"days/cycle)":[166],"420mg":[169],"po":[170],"(1-3":[171],"hours":[172],"before":[173],"starting":[174],"infusion),":[176],"daily":[178],"up":[180],"3":[182,315,493],"years.":[183,219],"All":[184],"prophylactic":[187],"medications.":[188],"were":[190,287,295,345,417,453],"assessed":[191],"by":[194,458,536],"criteria":[197,461],"two":[198],"months":[199,582],"after":[200,580],"completion":[201],"G,":[203],"as":[204,656,688],"primary":[206],"efficacy":[207],"endpoint.":[208],"median":[210,242],"age":[211],"was":[215,248,389,401,506],"(range:":[217],"46-78)":[218],"84%":[220,467],"had":[224,229,236,302,354,512],"CIRS":[226],">6,":[227],"45%":[228],"Rai":[231],"stage":[232],"III-IV":[233],"19%":[235],"ECOG":[238],"performance":[239],"\u22642.":[240],"baseline":[243,478],"absolute":[244],"lymphocyte":[245],"count":[246],"(ALC)":[247],"79x103/mm3(range:":[249],"1.4-412.4).":[250],"showed":[252,274,313,471],"following":[254],"FISH/cytogenetic":[255],"abnormalities:":[256],"del(13q)":[257],"55%,":[259],"trisomy":[260],"12":[261],"23%":[263],"del(11q)":[265],"19%.":[267],"Only":[268],"2":[269,443],"(6%)":[270,353,385],"these":[272],"del(17p).":[275],"From":[276],"IGVH":[280],"mutational":[281],"status":[282],"available":[283],"(n=17),":[284],"11":[285,465],"(65%)":[286],"unmutated":[288],"(>98%":[289],"homology).":[290],"Most":[291],"adverse":[292],"events":[293],"(AEs)":[294],"grade":[296,303,314,329,336,355,436,442,447,607,611],"1-2":[297,304,608],"(74%).":[298],"Six":[299],"(19%)":[301],"G-infusion-related":[305],"reaction":[306],"(IRR)":[307],"only":[309,486],"one":[310,388],"patient":[311,359,368],"(3%)":[312],"IRR":[316],"(without":[317],"need":[319],"discontinuation).":[322],"We":[323],"observed":[324],"neutropenia":[325],"(all":[326,333,341],"grades:":[327,334,342],"52%,":[328],"3-4:":[330,337],"23%),":[331],"thrombocytopenia":[332,449],"71%,":[335],"19%)":[338],"anemia":[340],"26%).":[343],"There":[344],"no":[346],"cases":[347],"febrile":[349],"neutropenia.":[350],"Two":[351,383],"1":[356,437],"bleeding":[357,364],"(one":[358],"asymptomatic":[361],"lower":[362],"gastrointestinal":[363],"second":[367],"epistaxis)":[370],"resolved":[372],"spontaneously":[373],"without":[374,571],"requirement":[375],"blood":[377],"transfusion":[378],"discontinuation.":[382],"developed":[386],"pneumonia,":[387],"community-acquired":[390],"pneumonia":[391],"requiring":[392],"inpatient":[393],"IV":[396],"antibiotics;":[397],"held":[402],"until":[403],"resolution":[404],"symptoms":[406],"re-initiated":[408],"at":[409,662,672,694,704],"full":[410],"dose.":[411],"frequent":[414],"non-hematological":[415],"AEs":[416,549],"diarrhea,":[418],"transaminitis,":[419],"hyperbilirubinemia,":[420],"hyperglycemia,":[421],"electrolyte":[423],"alterations":[424],"(grade":[425],"1-2).":[426],"Three":[427],"(9%)":[429],"discontinued":[430,566],"due":[432],"atrial":[434],"fibrillation":[435],"(n=1),":[438,444],"rash":[439],"headaches":[441],"persistent":[446],"4":[448],"(n=1).":[450],"Twenty-three":[451],"evaluable":[454,520,576],"assessment":[457],"(median":[462],"follow-up":[463,570],"months).":[466],"rapid":[473],"decrease":[474],"ALC":[476,500],"from":[477],"during":[479],"first":[481],"cycle":[482],"four":[487],"(13%)":[489],"required":[490],"more":[491],"achieve":[498],"response.":[501],"100%.":[507],"majority":[509],"partial":[514],"six":[517],"23":[519],"(26%)":[522],"achieved":[523,578],"remission":[526],"detectable":[528],"Minimal":[529],"Residual":[530],"Disease":[531],"bone":[534],"marrow":[535],"multiparametric":[537],"flow":[538],"cytometry.":[539],"In":[540],"summary,":[541],"Ibr-G":[542],"been":[545,551,599],"generally":[546],"well":[547],"tolerated.":[548],"consistent":[552],"known":[555],"safety":[556],"profiles":[557],"individually.":[562],"remain":[568],"disease":[572],"progression.":[573],"100%":[574],"therapy,":[585],"26%":[587],"met":[590],"CR":[591],"criteria.":[592],"One":[593],"important":[594],"finding":[595],"thus":[596],"far":[597],"very":[601],"IRR,":[605],"(19%":[606],"3%":[610],"3-4),":[612],"suggesting":[613],"strongly":[617],"mitigate":[618],"incidence":[620],"severity":[622],"associated":[625],"IRR.":[626],"Disclosures":[627],"Choi:":[628],"AbbVie,":[629],"Inc:":[630,763,810],"Consultancy,":[631,640,723,741,758,764,768],"Speakers":[632,637,643,646],"Bureau;":[633,638,644],"Rigel:":[634],"Consultancy;":[635,745,808,811],"Gilead:":[636,757],"Pharmacyclics:":[639,722],"Research":[641,652,684,735,742,760,765,780],"Funding,":[642],"Genentech:":[645],"Bureau.":[647],"Amaya-Chanaga:AbbVie:":[648],"Equity":[649],"Ownership,":[650],"Other:":[651,683],"performed":[653,669,685,701],"while":[654,670,686,702],"employed":[655,671,687,703],"investigator":[658,690],"this":[660,692],"UCSD.":[663,695],"Review":[664,696],"approval":[666,698],"abstract":[668,700],"Pharmacyclics,":[673,678,705,812],"LLC,":[674,706,813],"AbbVie":[676,680,708,815],"Company.;":[677],"Company:":[681],"Employment,":[682],"Company..":[709],"Kipps:Janssen:":[710],"Honoraria,":[711,724,759,769,783],"Membership":[712,725,747,770,784,795],"entity's":[715,728,750,773,787,798],"Board":[716,729,751,774,788,799],"Directors":[718,731,753,776,790,801],"advisory":[720,733,755,778,792,803],"committees;":[721,756,793],"committees,":[734,779],"Funding;":[736,743,761,766,781],"F.":[737],"Hoffmann-La":[738,806],"Roche":[739],"Ltd:":[740],"Celgene:":[744],"Verastem:":[746,794],"Genentech":[762],"AbbVie:":[767],"Janssen:":[782],"committees.":[804],"Castro:F.":[805],"Roche:":[807],"Genentech,":[809],"Company::":[816],"Consultancy.":[817]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-05-12T00:00:00"}